If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The decision marks a key step in the centralized EU review process
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
